This site is intended only for healthcare professionals resident in the Republic of Ireland
Ngenla®▼ (Somatrogon Injection) the once-weekly growth hormone (GH) for the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.1
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SPC for how to report adverse reactions.
Genotropin is a growth hormone therapy indicated for the treatment of growth disturbance in children due to insufficient secretion of growth hormone (growth hormone deficiency, GHD) and growth disturbance associated with Turner Syndrome or chronic renal insufficiency (CRI) or growth disturbance in short children born small for gestational age (SGA) with a birth weight and/or length below –2SD, who failed to show catch-up growth by 4 years of age or later.2
Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 concentrations or was not tolerated.3
Somavert Prescribing Information
Genotropin Prescribing Information
Ngenla Prescribing Information
Learn more about patient resources available to support your patients.
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023